Quick reference
Frequently needed definitions and tables, transcribed from the guideline (pp. 8–9, 15–17, 22).
Definition of heart failure (§3.1)
A clinical syndrome comprising signs and/or symptoms caused by structural and/or functional abnormalities of the heart that result in elevated intracardiac pressures and/or inadequate cardiac output at rest and/or during exercise. Objective evidence of cardiogenic congestion and supportive diagnostic tests are needed. Asymptomatic people are classified as at risk (stage A) or pre-HF (stage B).
Phenotypes by LVEF (§3.3.1)
The 2026 guideline eliminates HFmrEF and uses two phenotypes.
HFrEF
LVEF <50% and symptoms and/or signs of HF.
HFpEF
LVEF ≥50%, symptoms and/or signs of HF, and objective evidence of structural and/or functional abnormalities consistent with LV diastolic dysfunction/raised filling pressures, supported by raised natriuretic peptides.
Other classifications: de novo vs pre-existing; chronic vs decompensated; isolated left-sided vs right-sided vs combined (§3.3.3).
NYHA functional class (Table 8)
- Class I
- No limitation of physical activity. Ordinary activity does not cause undue breathlessness, fatigue or palpitations.
- Class II
- Slight limitation. Comfortable at rest, but ordinary activity causes undue breathlessness, fatigue or palpitations.
- Class III
- Marked limitation. Comfortable at rest, but less than ordinary activity causes undue breathlessness, fatigue or palpitations.
- Class IV
- Unable to carry on any physical activity without discomfort; symptoms may be present at rest.
NT-proBNP age-adjusted thresholds (§5.1.1)
Outpatient levels above which HF is “likely”: ≥125 pg/mL for age <50 y, ≥250 pg/mL for 50–75 y, ≥500 pg/mL for >75 y (HFA-ESC consensus). The 2021 single rule-out value was <125 pg/mL NT-proBNP (<35 pg/mL BNP). Obesity lowers natriuretic peptide levels — interpret with caution. See Table 9 and Figure 4 on pp. 23–24.
Classes of recommendation (Table 1)
- Class I“is recommended / indicated”
- Class IIa“should be considered”
- Class IIb“may be considered”
- Class III“is not recommended”
Levels of evidence — therapy (Table 2)
- Level A
- Conclusive evidence, usually from at least two adequately powered RCTs free of major bias (meta-analysis P <0.005).
- Level B1
- Suggestive evidence from at least one adequately powered RCT free of major bias, or a meta-analysis of such RCTs (P <0.05).
- Level B2
- Limited evidence from ≥2 adequately powered non-randomized studies with careful bias control, or a meta-analysis of small underpowered RCTs.
- Level C
- Preliminary evidence: non-randomized studies without careful bias control, a single small RCT, or expert consensus.
Treatment nomenclature (§3.3.4)
FMT foundational medical therapy · AMT additional medical therapy · GDIT guideline-directed interventional therapy. FMT for HFrEF: ACE-I/ARNI (or ARB), beta-blocker, MRA, SGLT2-I; SGLT2-I and MRA are recommended in all symptomatic HF regardless of LVEF. Doses are in the drug dose table.